Tejal A. Desai

Tejal A. Desai

Auto-generated profile, based on publicly available information

Tejal A. Desai

University of Illinois at Chicago

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Medical Engineering & Physics
Verified
Journal Article
Closed access
TDTejal A Desai
Tejal A Desai

1 January 2000 in Journal of Biomedical Materials Research
Verified
Journal Article
Closed access
PDF file
JDJennifer Deutsch
Jennifer Deutsch
DMDelara Motlagh
Delara Motlagh
BRBrenda Russell
Brenda Russell
TDTejal A. Desai
Tejal A. Desai

1 November 2000 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
TDTejal A Desai
Tejal A Desai
DHDerek J Hansford
Derek J Hansford
LLLara Leoni
Lara Leoni
MEMatthias Essenpreis
Matthias Essenpreis
MFMauro Ferrari
Mauro Ferrari

1 October 2000 in Biomolecular Engineering
Verified
Journal Article
Closed access
TDTejal A Desai
Tejal A Desai
DHDerek J Hansford
Derek J Hansford
MFMauro Ferrari
Mauro Ferrari

1 June 1999 in Biomedical Microdevices
Verified
Journal Article
Closed access
PDF file
TDTejal A. Desai
Tejal A. Desai
WCWen Hwa Chu
Wen Hwa Chu
GRGuido Rasi
Guido Rasi
PSPaola Sinibaldi
Paola Sinibaldi
EGEnrico Guarino
Enrico Guarino
MFMauro Ferrari
Mauro Ferrari

1 August 2002 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
TDTejal A Desai
Tejal A Desai
The inadequacy of conventional insulin therapy for the treatment of Type I diabetes has stimulated research on several therapeutic alternatives, including insulin pumps and controlled-release systems for insulin. One of the most physiological alternatives to insulin injections is the transplantation of insulin-secreting cells. It is the β-cells of the islets that secrete insulin in response to increasing blood glucose concentrations. Ideally, transplantation of such cells (allografts or xenografts) could restore normoglycaemia. However, as with most tissue or cellular transplants, the cellular grafts, particularly xenografts, are subject to immunorejection in the absence of chronic immunosuppression. Thus, it is of great interest to develop new technologies that may be used for insulin delivery or pancreatic cell transplantation. This review describes a new approach to cellular delivery based on micro- and nanotechnology. Utilising this approach, nanoporous biocapsules are bulk and surface micromachined t...